NIPOCALIMAB
UNII 87M90CV8NC

Substance Identification & Data

This profile provides standardized clinical and technical data for Nipocalimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 87M90CV8NC.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2211985-36-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

87M90CV8NC

CAS Registry Number

2211985-36-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NIPOCALIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

87M90CV8NC

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C170891

National Cancer Institute reference terminology for clinical and research data.

INN ID

11215

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FG-218

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Nipocalimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

NIPOCALIMAB

NIPOCALIMAB-AAHU

Common Names & Synonyms

IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS FCGRT (FC FRAGMENT OF IGG RECEPTOR AND TRANSPORTER, NEONATAL FC RECEPTOR, FCRN, TRANSMEMBRANE ALPHA CHAIN OF THE NEONATAL RECEPTOR)), HOMO SAPIENS MONOCLONAL ANTIBODY (GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-445) (VH (HOMO SAPIENS IGHV3-23*01 (90.8%) -(IGHD) -IGHJ3*01 (100%)) CDR-IMGT (8.8.9) (26-33.51-58.97-105) (1-116) -HOMO SAPIENS IGHG1*03 G1M3>G1M17, NG1M1, G1V29 CH2 A84.4 (CH1 R120>K (213) (117-214), HINGE 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>DEL (445)) (117-445)), (219-215')-DISULFIDE WITH LAMBDA LIGHT CHAIN HOMO SAPIENS (1'-216') (V-LAMBDA (HOMO SAPIENS IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT (9.3.10) (26-34.52-54.91-100) (1'-110') -HOMO SAPIENS IGLC3*03 (100%) (111'-216')); DIMER (225-225'':228-228'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, NON-GLYCOSYLATED)

NIPOCALIMAB [INN]

NIPOCALIMAB [USAN]

NIPOCALIMAB [WHO-DD]

NIPOCALIMAB AAHU [WHO-DD]

Brand / Trade Names

IMAAVY

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN NEONATAL FC RECEPTOR) (HUMAN MONOCLONAL M281 .GAMMA.-1 CHAIN), DISULFIDE WITH HUMAN MONOCLONAL M281 .LAMBDA.-CHAIN, DIMER

SYS